NCT06674382Recruiting
Haplo-HSCT for Myelofibrosis
Haploidentical Hematopoietic Stem Cell Transplantation for the Treatment of Myelofibrosis: A Prospective, Single-center Study
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Brief summary (registry, in English)
Myelofibrosis (MF) is a myeloproliferative neoplasm causing bone marrow failure and high risk of leukemia transformation. JAK2 inhibitors improve symptoms but do not cure MF. Allogeneic stem cell transplantation (allo-HSCT) is the only potential cure, though limited donor availability restricts access. Haploidentical transplantation shows promise but associated with higher graft failure and treatment related mortality. We recently developed a novel regimen of haplo-SCT for MF. This study aims to investigate this novel protocol in a prospective trial to improve MF outcomes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 39 (estimated)
- First submitted
- 3 Nov 2024
- Start date
- 1 Jan 2024
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Myeloproliferative neoplasms
- NCT number
- NCT06674382
What you commit to
- Study type: Interventional
- Planned participants: 39
- From 1 Jan 2024 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Active infection
Other
- Very poor performance status (ECOG score \> 2)
- Estimated survival time \< 30 days
- Patient or family unable to cooperate
- Considered unsuitable after discussion
Who the study is looking for
- Primary disease type: Myelofibrosis (including primary myelofibrosis and myelofibrosis secondary to polycythemia vera or essential thrombocythemia).
- No matched sibling donor or unrelated donor, with the availability of a haploidentical donor.
- Signed informed consent.
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.